Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-637 monotherapy or combination in solid tumors
NCT04721015Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2021
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
Phase 1, open-label trial of ABBV-637 in solid tumor and non-small cell lung cancer (NSCLC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events up to 3 years and Objective Response Rate up to 3 years. Started Feb 2021; status: active, not recruiting.
02
Drugs
ABBV-637
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04721015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04721015.